Xenon to Report Q2 2024 Financial Results on August 8, 2024
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their lead product, Azetukalner, a Kv7 channel opener, is in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator in its class.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), una società biofarmaceutica focalizzata sulle neuroscienze, ha annunciato che riporterà i suoi risultati finanziari e operativi del secondo trimestre del 2024 dopo la chiusura dei mercati finanziari statunitensi di giovedì 8 agosto 2024. L'azienda ospiterà una conference call e una diretta web alle 16:30 ora orientale dello stesso giorno per discutere i risultati.
Xenon è dedicata alla scoperta, sviluppo e fornitura di terapie che cambiano la vita per pazienti con disturbi neurologici e psichiatrici. Il loro prodotto di punta, Azetukalner, un apritore del canale Kv7, è in fase avanzata di sviluppo clinico per più indicazioni, rappresentando il modulatore del canale del potassio clinicamente più avanzato e convalidato nella sua categoria.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), una empresa biofarmacéutica centrada en neurociencias, ha anunciado que reportará sus resultados financieros y operativos del segundo trimestre de 2024 después de la cierre de los mercados financieros de EE. UU. el jueves 8 de agosto de 2024. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 4:30 p. m. hora del este el mismo día para discutir los resultados.
Xenon se dedica a descubrir, desarrollar y ofrecer terapias que cambian la vida para pacientes con trastornos neurológicos y psiquiátricos. Su producto principal, Azetukalner, un abridor de canal Kv7, se encuentra en fase avanzada de desarrollo clínico para múltiples indicaciones, representando el modulador de canal de potasio clínicamente más avanzado y validado en su clase.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), 신경과학에 중점을 둔 생명공학 회사는 2024년 2분기 재무 및 운영 결과를 2024년 8월 8일 목요일에 미국 금융 시장이 폐장한 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 결과를 논의하기 위한 컨퍼런스 콜 및 웹 세미나를 개최할 예정입니다.
Xenon은 신경 및 정신 장애가 있는 환자를 위한 삶을 변화시키는 치료제를 발견, 개발 및 제공하는 데 전념하고 있습니다. 그들의 주요 제품인 Azetukalner는 Kv7 채널 오프너로, 여러 적응증에 대한 후기 단계 임상 개발 중이며, 해당 클래스에서 가장 진보하고 임상적으로 검증된 칼륨 채널 조절제입니다.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), une entreprise biopharmaceutique axée sur les neurosciences, a annoncé qu'elle publiera ses résultats financiers et opérationnels du deuxième trimestre 2024 après la fermeture des marchés financiers américains le jeudi 8 août 2024. L'entreprise organisera une conférence téléphonique et une webdiffusion le même jour à 16h30, heure de l'Est, pour discuter des résultats.
Xenon s'engage à découvrir, développer et fournir des thérapies qui changent la vie pour les patients atteints de troubles neurologiques et psychiatriques. Leur produit phare, Azetukalner, un ouvreur de canal Kv7, est en phase avancée de développement clinique pour plusieurs indications, représentant le modulateur de canal potassique le plus avancé et cliniquement validé de sa catégorie.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), ein biopharmazeutisches Unternehmen mit Fokus auf Neurowissenschaften, hat angekündigt, dass es seine Finanz- und Betriebsergebnisse für das zweite Quartal 2024 nach Schließung der US-Finanzmärkte am Donnerstag, den 8. August 2024 berichten wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen.
Xenon hat sich der Entdeckung, Entwicklung und Bereitstellung von lebensverändernden Therapeutika für Patienten mit neurologischen und psychiatrischen Erkrankungen verschrieben. Ihr Spitzenprodukt, Azetukalner, ein Kv7-Kanalöffner, befindet sich in der späten klinischen Entwicklungsphase für mehrere Indikationen und stellt den fortschrittlichsten und klinisch validierten Kaliumkanalmodulator seiner Klasse dar.
- Xenon has a novel product pipeline addressing high unmet medical needs in epilepsy and depression
- Azetukalner, the company's lead product, is in late-stage clinical development for multiple indications
- None.
Conference Call and webcast scheduled at 4:30 pm ET
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024.
Conference Call/Webcast Information:
| Date: | Thursday, August 8, 2024 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | Pre-register here |
| Dial-In: | (800) 715-9871 toll-free, or (646) 307-1963 for international callers |
| Conference ID: | 1631616 |
The live audio webcast can be accessed on the Investors section of the Xenon website. A replay of the webcast will be posted on the website approximately one hour after the conclusion of the event and will remain available for approximately one month. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals (XENE) report its Q2 2024 financial results?
What time is Xenon Pharmaceuticals' (XENE) Q2 2024 earnings call scheduled for?
What is Xenon Pharmaceuticals' (XENE) lead product in development?
What therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?
